Navigation Links
Leading Oncologists from Across the Country Hold Emergency Meeting on New Government Reimbursement Policy for Medicare Patients with Cancer
Date:10/24/2007

Oncologists Point to Science, Quality Outcomes, Safety Concerns and Interference with Doctors' Expertise as Reasons to Revisit NCD

CHICAGO, Oct. 24 /PRNewswire-USNewswire/ -- Leading oncologists from across the country gathered in Chicago today to discuss concerns and reach consensus over the new National Coverage Decision (NCD) for the use of Erythropoiesis Stimulating Agents (ESAs) in cancer treatments for Medicare patients. The meeting, which brought together approximately 50 of the nation's leading oncologists, was chaired by Dr. Peter Ellis, Medical Director of the University of Pittsburgh's Medical Center (UPMC) Cancer Centers.

ESAs are used to boost patients' red blood cell counts when undergoing chemotherapy, which allows them to better cope with the treatment regimen. The NCD is putting restrictions on Medicare reimbursement for hemoglobin levels at 10g/dL. Since the new NCD guidelines were first introduced in late July by the Centers for Medicare and Medicaid Services (CMS), oncologists and patients from across the country have come forward expressing concern over what many regard as interference by the government on cancer doctors' medical decisions for their patients.

The oncologists created a statement today based on remarks from leading health policy experts and a satellite briefing from Washington, DC featuring physicians who had participated in meetings at the Centers for Medicare and Medicaid Services (CMS) where they discussed revisiting the NCD allowing doctors to administer ESAs before a patient's hemoglobin level drops below 10. Since Medicare will not reimburse at any amount above a hemoglobin level of 10, patients could be subjected to blood transfusions which many oncologists regard as unnecessary and expose the patient to added health risks.

The final statement, which is being sent to policymakers in Washington and widely distributed among their peers and patient groups across the country, reads as follows:

We support an evidence-based uniform coverage policy for anemia management of Medicare patients undergoing chemotherapy treatment through the development of a National Coverage Determination (NCD), and share CMS' concern regarding the safety of Erythropoiesis Stimulating Agents (ESAs) when administered to patients who are above the hemoglobin (hgb) level of 12g/dL.

Over 40 scientific studies support the safe and effective use of ESAs in chemotherapy induced anemia when administered up to hgb 12g/dL. There is no evidence of tumor progression or increased mortality in the use of ESAs in accordance with the FDA label up to hgb 12g/dl.

The current NCD poses significant health risks to Medicare cancer patients. As no published research indicates that stopping ESAs at hgb of 10g/dL will be safe or effective, this policy exposes cancer patients to needless blood transfusions with associated risks.

The NCD, by limiting our ability to use supportive care drugs appropriately, hinders oncologists' ability to provide life saving or life prolonging treatments and will impose different, less effective cancer treatment regimens.

The NCD does not acknowledge the valuable improvements in quality of life which numerous studies have documented to be derived from appropriate ESA usage.

The NCD forces physicians and patients to choose between the standard of care versus what Medicare's coverage policy will reimburse thus creating a two-tiered system of care where Medicare patients receive substandard care.

We urge CMS to:

1- Acknowledge as the clinical standard of care for determining

medical necessity in the use of ESAs the October 22, 2007

evidence-based guidelines for patient treatment established by the

American Society of Clinical Oncology (ASCO) and the American

Society of Hematology (ASH);

2- Reconsider the ESA NCD and alter the final coverage determination to

reflect the ASCO-ASH guidelines.


'/>"/>
SOURCE US Oncology
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Is Diabetes the Leading Cause of Kidney Failure in India
2. Misleading anti-malarial drug
3. Misleading Advertisements for Prescription Drugs
4. The Effects Of Smoking Misleading
5. Antidepressant Medication Leading To Suicidal Thoughts
6. Leading Biotech Companies Are Interested In Acquisition Of Smaller Companies
7. Historic trial for tuberculosis launched together by leading drug companies
8. Alcohol And Drug Abuse (Cannabis) Leading Causes For Road Traffic Accidents
9. Down’s Syndrome Is The Leading Birth Defect In the U
10. Exposure to Grating, Noise, Music Can Cause Tumors Leading To Deafness
11. Bottleneck: High on Spirits Can Cause A Dispirited Liver, Leading To Cirrhosis!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 2017 , ... Pink Pig Publishing LLC announces the launch ... the world from different perspectives. By providing a place for people of all ... empathy, and find greater happiness. , "Our approach to structuring content is ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare ... for those in the fight against cancer, has produced a seminal study that ... HRA will release top-line findings in a webinar, Defining Compassionate Care Through the ...
(Date:2/23/2017)... ... 23, 2017 , ... CALNOC, the nation’s first and only nursing quality indicators ... – Empowerment, Value and Collaboration – in Seattle, WA on October 23, 2017. , ... Health System in Seattle since 2000. In addition to his role at Virginia Mason, ...
(Date:2/23/2017)... ... February 23, 2017 , ... HealthPostures, the desk for standing ... sit stand solutions representative to the Minneapolis Home and Garden Show which is being ... that is garnering national attention is the Minneapolis Convention Center. , From its ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... a new healthcare contact center in Georgia, PENETRON Specialty Products (PSP) provided the ... largest healthcare systems recently invested $51 million to purchase and renovate the 185,000 ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb 23, 2017 ... Research and Markets has announced the addition ... Forecast to 2025" report to their offering. The ... around 1.8% over the next decade to reach approximately $12.8 billion by ... and forecasts for all the given segments on global as well as ...
(Date:2/23/2017)... YORK , February 23, 2017 ... its report on the global market for intraoperative ... be presently valued at US$ 513.9 million. According ... will keep surging on the grounds of increasing ... in the field of diagnostic imaging for neurosurgeries. ...
(Date:2/23/2017)... -- LG Innotek today announced that the company has developed the ... performance is 1.5 times higher than the competitor,s 45mW module. ... range of 200 -- 280nm, allowing it to be used for sterilization ... LG Innotek,s product emits UV in the range of 280nm. ... Until now, UV-C LED ...
Breaking Medicine Technology: